ADmit THERAPEUTICS - test for an early AD detection. Alzheimer's disease
test for an early AD detectionAlzheimer's disease
test for an early AD detectionAlzheimer's disease  


Our diagnostic test represents the determination of biomarkers non-related with β-amyloid nor tau. Therefore, our unique value proposition is that our test is based on an epigenetic analysis in blood samples, covering the analysis of a large number of methylcytosines in mtDNA by next generation sequencing. As systemic mitochondrial dysfunction has been proposed just before the appearance of cerebral abnormal protein aggregates, our findings may become a pool of biomarkers very useful for the detection of patients at early stages of AD.


It is envisioned that ADmit Therapeutics will develop a new laboratory-based IVD device, obtaining the corresponding CE mark in 2023.
This website uses cookies, both our own and third party cookies, to improve your online experience and collect statistical information on browsing patterns.
By continuing to use this website, you consent cookies being installed on your browser. More information on our Cookies Policy